Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index
Objective To investigate the impact of baseline and time‐varying factors on the risk of serious adverse events (SAEs) in patients during long‐term certolizumab pegol (CZP) treatment. Methods Safety data were pooled across 34 CZP clinical trials in rheumatoid arthritis (RA), axial spondyloarthritis (...
Main Authors: | Vivian P. Bykerk, Andrew Blauvelt, Jeffrey R. Curtis, Cécile Gaujoux‐Viala, Tore K. Kvien, Kevin Winthrop, Nicola Tilt, Christina Popova, Xavier Mariette, Boulos Haraoui |
---|---|
格式: | Article |
語言: | English |
出版: |
Wiley
2021-08-01
|
叢編: | ACR Open Rheumatology |
在線閱讀: | https://doi.org/10.1002/acr2.11259 |
相似書籍
-
Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials
由: Tore K Kvien, et al.
出版: (2019-05-01) -
Long-Term Durability of Certolizumab Pegol in Patients with Rheumatoid Arthritis Over 5 Years: An Analysis of Pooled Clinical Trial Data
由: Vivian P. Bykerk, et al.
出版: (2023-02-01) -
Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment
由: Jeffrey R. Curtis, et al.
出版: (2017-12-01) -
Certolizumab pegol in the treatment of spondyloarthritis
由: Mariusz Korkosz
出版: (2014-09-01) -
CERTOLIZUMAB PEGOL IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS
由: Sh. F. Erdes
出版: (2016-02-01)